Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.

Meng Z, Wang Y, Zhang G, Ke Y, Yan Y, Wu L, Huang Q, Zeng G, Wang Y, Ying H, Jiao S.

J Immunother. 2011 Sep;34(7):525-34. doi: 10.1097/CJI.0b013e318226bd45.

2.

Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.

Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P.

J Immunol. 2006 Nov 15;177(10):6769-79.

3.

A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.

Larrieu P, Ouisse LH, Guilloux Y, Jotereau F, Fonteneau JF.

Cancer Immunol Immunother. 2007 Oct;56(10):1565-75.

PMID:
17318652
4.

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.

Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, Sidney J, Sette A, Storkus WJ.

Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):400-5.

5.
6.

Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.

Bettinotti MP, Kim CJ, Lee KH, Roden M, Cormier JN, Panelli M, Parker KK, Marincola FM.

J Immunol. 1998 Jul 15;161(2):877-89.

8.

Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles.

Godefroy E, Scotto L, Souleimanian NE, Ritter G, Old LJ, Jotereau F, Valmori D, Ayyoub M.

Clin Immunol. 2006 Oct;121(1):54-62.

PMID:
16814609
9.

Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype.

D'Souza S, Rimoldi D, Líenard D, Lejeune F, Cerottini JC, Romero P.

Int J Cancer. 1998 Dec 9;78(6):699-706.

10.

Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A.

Jäger E, Höhn H, Karbach J, Momburg F, Castelli C, Knuth A, Seliger B, Maeurer MJ.

Int J Cancer. 1999 Jun 11;81(6):979-84.

11.
12.

Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.

Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, van der Bruggen P, Schuler G.

J Immunol. 2004 Jan 15;172(2):1304-10.

13.

Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones.

Kirkin AF, thor Straten P, Hansen MR, Barfoed A, Dzhandzhugazyan KN, Zeuthen J.

Cancer Immunol Immunother. 1999 Aug;48(5):239-46.

PMID:
10478640
14.

Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.

Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N.

J Immunol. 2003 Dec 1;171(11):6283-9.

15.

Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.

Christensen O, Lupu A, Schmidt S, Condomines M, Belle S, Maier A, Hose D, Neuber B, Moos M, Kleist C, Terness P, Ho AD, Goldschmidt H, Klein B, Hundemer M.

J Immunother. 2009 Jul-Aug;32(6):613-21. doi: 10.1097/CJI.0b013e3181a95198.

PMID:
19483648
16.

Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.

Valmori D, Fonteneau JF, Lizana CM, Gervois N, Liénard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P.

J Immunol. 1998 Feb 15;160(4):1750-8.

17.

Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.

Skipper JC, Gulden PH, Hendrickson RC, Harthun N, Caldwell JA, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr.

Int J Cancer. 1999 Aug 27;82(5):669-77.

18.

One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.

Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM.

J Immunol. 2005 Feb 1;174(3):1751-9.

19.

Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.

Pérez-Díez A, Butterfield LH, Li L, Chakraborty NG, Economou JS, Mukherji B.

Cancer Res. 1998 Dec 1;58(23):5305-9.

20.

Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.

Carrabba MG, Castelli C, Maeurer MJ, Squarcina P, Cova A, Pilla L, Renkvist N, Parmiani G, Rivoltini L.

Cancer Res. 2003 Apr 1;63(7):1560-7.

Items per page

Supplemental Content

Support Center